

## AMENDMENT TO THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1. (Currently amended) An isolated, synthetic or recombinant  $\chi$ -conotoxin peptide comprising the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; ~~or such a sequence in which~~ optionally one or more Cys is replaced with its corresponding D-amino acid, ~~and/or~~ optionally Pro has been replaced with 4-hydroxyproline, ~~and/or~~ and optionally Tyr is substituted with 4-methoxy tyrosine; or a salt or amide thereof.

2. (Currently amended) The peptide according to claim 1 consisting of the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; ~~or such a sequence in which~~ optionally one or more Cys is replaced with its corresponding D-amino acid, ~~and/or~~ optionally Pro has been replaced with 4-hydroxyproline, ~~and/or~~ and optionally Tyr is substituted with 4-methoxy tyrosine; or a salt or amide thereof.

3. (Previously presented) The peptide according to claim 1 wherein Pro has been replaced with 4-hydroxyproline.

4. (Currently amended) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 4

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Xaa5 SEQ ID NO. 5;

Xaal Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys SEQ ID NO. 6;

Xaal Asn Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys SEQ ID NO. 7

Xaal Asn Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 8

or

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 9;

where Xaal is N-terminal pGlu, Xaa3 is 4-hydroxyproline, Xaa4 is 4-methoxy tyrosine, Xaa5 is D-cysteine and -OH indicates a free acid C terminal.

5. (Previously presented) The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH SEQ ID NO. 10

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys SEQ ID NO. 11

where Xaal is DpGlu, Xaa3 is 4-hydroxyproline and -OH indicates a free acid C terminal.

6. (Previously presented) A composition comprising the peptide of any one of claims 1 to 5 together with pharmaceutically acceptable carrier or diluent.

7. (Original) The composition of claim 6 further comprising one or more other active agents.

8-14. (Canceled)

15. (Previously presented) An isolated, synthetic or recombinant  $\chi$ -conotoxin peptide or a salt, ester or amide thereof, wherein said peptide comprises the following amino acid sequence:

pGlu Gly Val Cys Cys Gly Tyr Lys Leu Cys His Hyp Cys (SEQ ID NO: 4).

16. (Previously presented) An isolated, synthetic or recombinant amidated  $\chi$ -conotoxin peptide, wherein said peptide comprises the following amino acid sequence:

pGlu Gly Val Cys Cys Gly Tyr Lys Leu Cys His Hyp Cys (SEQ ID NO: 4),

and wherein the C-terminal Cys residue is amidated.

17. (Withdrawn and currently amended) A method for the treatment or control of acute, chronic and/or neuropathic pain, migraine or ~~inflammation~~ inflammatory pain in a mammal

comprising administering to the mammal an effective amount of an isolated, synthetic or recombinant  $\chi$ -conotoxin peptide of any one of claims 1-5 or 15-16.

18. (Withdrawn and currently amended) The method of claim ~~17~~22, wherein the neuropathic pain is associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, or nerve damage, ~~inflammatory pain and peripheral nerve associated pain.~~

19. (Withdrawn and currently amended) The method of claim 17, wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of ~~said conditions, diseases or disorders, or said pain~~[[,]] or migraine or inflammation.

20-21. (Canceled)

22. (Withdrawn-New) The method of claim 17, wherein said method is for the treatment and control of neuropathic pain.